Cardioversion of atrial fibrillation - Can we predict success using copeptin?

P02.07 PhD Day 2019, Aarhus University:

Cardioversion of atrial fibrillation: Can we predict success using copeptin?

The study aims to investigate if successful outcome after electrical direct current cardioversion of atrial fibrillation can be predicted based on the biomarker copeptin. Cardioversion is an important treatment option, which aims to reduce disease burden. However, cardioversion is not always successful, and recurrence of atrial fibrillation is present in 50- 80% of patients after one year. Copeptin is a novel biomarker associated with cardiovascular morbidity. In this study, we aimed to investigate the association between copeptin and outcomes after cardioversion of atrial fibrillation.

Patients undergoing elective cardioversion of atrial fibrillation were included. The level of copeptin was determined before cardioversion and at 90-day follow-up. The data are a post-hoc analysis of a previous study